JPRN-jRCT2080223287已完成3 期
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease(A4 Study)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 65age old 至 <= 85age old（—）
- 性别
- All
入选标准
- •MMSE score at screening of 25 to 30
- •global CDR score at screening of 0
- •Logical Memory II score at screening of 6 to 18
- •Florbetapir PET scan that shows evidence of brain amyloid pathology
- •Has a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or electronic communication)
排除标准
- •-Is receiving a prescription acetylcholinesterase inhibitor (AChEI) and/or memantine at screening or baseline
- •-Lacks good venous access, such that intravenous drug delivery or multiple blood draws would be precluded
- •-Has current serious or unstable illness including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease or other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study
- •-Has had a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in protracted loss of consciousness
- •-Has had a history within the last 5 years of a primary or recurrent malignant disease with the exception of any in situ cancer that was appropriately treated and is being appropriately monitored, such as resected cutaneous squamous cell carcinoma in situ or in situ prostate cancer with normal prostate-specific antigen post-treatment
- •-Has a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis)
- •-Is clinically judged by the investigator to be at serious risk for suicide
- •-Has a history within the past 2 years of major depression or bipolar disorder as defined by the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM)
- •-Has a history within the past 5 years of chronic alcohol or drug abuse/dependence as defined by the most current version of the DSM
研究者
相似试验
已完成
2 期
A randomised trial for the treatment of AL amyloidosis with the high dose Green Tea Extract.ligh chain amyloidosisJPRN-UMIN000019732Japanese Red Cross Medical Center, Division of Hematology60
招募中
Unknown
Dementia treatment with combination of hydrogen gas and reduced dose lithium.Alzheimer's dementiaJPRN-jRCT1091220303Hirohisa Ono50
已完成
3 期
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory LossCognition DisordersNCT02008357Eli Lilly and Company1,169
招募中
不适用
Clinical Implementation of Amyloid Neurodegeneration and Tau testing in Primary Care.Alzheimer's diseaseNL-OMON56307Vrije Universiteit Medisch Centrum400
已完成
不适用
ithium for mild-to-moderate Alzheimer's disease: A randomized double-blind, placebo-controlled studyAlzheimer's diseaseJPRN-UMIN000020128Department of Psychiatry, Fujita Health University School of Medicine100